
Louis Archambault
Chercheur universitaire
Axe Oncologie
Physique médicale
Instrumentation optique
Radiologie, médecine nucléaire et imagerie médicale
Modèles informatiques
Calcul numérique
Publications
Voir tout-
article Safari M, Yang X, Fatemi A, Archambault L
MRI motion artifact reduction using a conditional diffusion probabilistic model (MAR-CDPM)
Med Phys 51 (4), 2024.
-
article van den Dobbelsteen M, Lessard B, Côté B, Hackett SL, Mugnes JM, Therriault-Proulx F, Lambert-Girard S, Uijtewaal P, de Vries LJM, Archambault L, Bosma T, van Asselen B, Raaymakers BW, Fast MF
An improved calibration procedure for accurate plastic scintillation dosimetry on an MR-linac
Phys Med Biol 69 (24), 2024.
-
article Safari M, Yang X, Chang CW, Qiu RLJ, Fatemi A, Archambault L
Unsupervised MRI motion artifact disentanglement: introducing MAUDGAN
Phys Med Biol 69 (11), 2024.
Projets
- NSERC CREATE in Responsible Health and Healthcare Data Science, du 2019-09-01 au 2026-08-31
- Engineering bioactive dressings from mesenchymal cells to enhance healing of irradiated skin wounds, du 2022-04-01 au 2027-03-31
- Propulsion d’une plateforme de dosimétrie à scintillation de pointe vers de nouvelles applications à fort potentiel innovant et commercial, du 2022-06-27 au 2026-12-31
- Expanding the boundaries of scintillation dosimetry with data science, signal processing and innovative design, du 2024-04-01 au 2029-03-31
- Enhancing the PARADIM platform to bridge the gap between data and AI in medical imaging, du 2024-09-01 au 2027-08-31
- Bringing three-dimensional dosimetry in the clinic for advanced quality control in radiation therapy, du 2025-01-13 au 2028-06-30
- New tools and method for monitoring ionizing radiation delivery in medical physics, du 2018-04-01 au 2024-03-31
- Validation clinique de l'Hyperscint MD, du 2023-10-18 au 2024-10-17
- Scale-up and validation of personalized outcome prediction model for newly diagnosed prostate cancer patients by integrating clinicopathological data and multi-task artificial , du 2024-06-17 au 2025-06-16
- 2SHARP:Two Fractions Study of Hypofractionated Ablative Radiotherapy for Prostate Cancer. , du 2024-06-19 au 2025-03-31